Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Psychiatric Disorders with Proven Dysimmunity
NCT05946486Phase 3Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Oct 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in psychotic disorders, bipolar disorder (BD), sponsored by Centre Hospitalier Universitaire de Bordeaux. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
psychotic disordersbipolar disorder (BD)
Beyond the preview
Go deeper on NCT05946486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05946486.